The Addition of Gemtuztumab Ozogamicin to Low Dose Ara C Improves Remission Rates but Not Survival Results of the UK LRF AML14 and NCRI AML16

Autoria(s): Burnett, Christine; Hills, R.; Hunter, A.E.; Milligan, D.; Kell, W.J.; Wheatley, K.; Yin, J.; McMullin, Mary Frances; Dignum, H.; Bowen, Linda; Russell, Norman
Data(s)

2010
Identificador

http://pure.qub.ac.uk/portal/en/publications/the-addition-of-gemtuztumab-ozogamicin-to-low-dose-ara-c-improves-remission-rates-but-not-survival-results-of-the-uk-lrf-aml14-and-ncri-aml16(c2a413c2-eae8-48c7-a283-586167aa45c3).html
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Burnett , C , Hills , R , Hunter , A E , Milligan , D , Kell , W J , Wheatley , K , Yin , J , McMullin , M F , Dignum , H , Bowen , L & Russell , N 2010 , ' The Addition of Gemtuztumab Ozogamicin to Low Dose Ara C Improves Remission Rates but Not Survival Results of the UK LRF AML14 and NCRI AML16 ' Blood , vol 116 , pp. 13-14 .
Tipo

article
Acesso ao item digital